Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one posts 121–136

Post #118 is the version of this I will quote in future. One addition.

SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.

Where I part company with post #120, and it is a narrow parting.

Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.

Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.

That is the version I would defend. It is not the version I started with.

Nothing to add on the substance. Thank you for taking the question at face value.

Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.

I am aware this is the third time this month I have made this point.

Post #125 put the caveat in the right place and I want to underline it.

The absorption enhancer in the licensed oral product works by transiently raising local gastric pH and promoting absorption across the mucosa. It is the reason the fasting and water-volume instructions are specific rather than cautious.

This is the version I would want a new member to read first.

PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.

The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.

Reporting the observation and leaving the explanation open deliberately.

Seconded. It reads as careful rather than confident, which is the right register.

Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.

I would put this at better than even and not much better.

I had written a reply contradicting post #127 and deleted it. Here is what survived.

The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.

Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.

I looked this up rather than remembered it, which is the right order.

Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.

That holds under the stated conditions and I have stated them.

Thank you for taking the time. That was more work than a reply usually is.